Latest Breaking News On - Serum institute of india astrazeneca - Page 2 : comparemela.com

Sputnik V to face stiff competition in India: GlobalData Sputnik V to face stiff competition in India: GlobalData 20 April 2021 | News Source credit: Shutterstock With the Sputnik V vaccine’s recent approval, India now has three vaccines authorised for COVID-19 treatment. However, despite better efficacy over Serum Institute of India/ AstraZeneca’s Covishield and Bharat Biotech’s COVAXIN, Sputnik V will face stiff competition in India, says GlobalData. Dr Reddy s Laboratories (DRL) will receive Sputnik V from the Russian Direct Investment Fund (RDIF) by mid-May 2021 and local production is expected to commence from July–September 2021 timeframe.   Sputnik V pricing will be key for gaining a solid foothold in India. Its price is expected to be slightly higher compared to Covishield and COVAXIN due to its higher efficacy. 

Prashant khadayateSerum institute of india astrazenecaIndia coRussian direct investment fundSerum instituteBharat biotechPharma analystIndia co winCadila healthcareஇந்தியா இணைரஷ்ய நேரடி முதலீடு நிதிசீரம் நிறுவனம்பாரத் பயோடெக்பார்மா ஆய்வாளர்காடிலா சுகாதாரம்